Effect of in-line filtration in newborns. Study protocol of the Intravenous Neonatal Central Access Safety (INCAS) randomized controlled trial.

Author:

Cresi Francesco1,Maggiora Elena1ORCID,Capetti Cecilia1ORCID,Capitanio Martina1,Ferroglio Mattia1,Spada Elena1,De Matteis Francesca2,Cosimi Sara3,Mosca Fabio4,Coscia Alessandra1

Affiliation:

1. University of Turin: Universita degli Studi di Torino

2. Azienda Ospedaliero Universitaria Citta della Salute e della Scienza di Torino

3. Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino: Azienda Ospedaliero Universitaria Citta della Salute e della Scienza di Torino

4. University of Milan, Department of Clinica Sciences and Community Health

Abstract

Abstract Background: Particulate contamination due to infusion therapy (administration of parenteral nutrition and medications) carries a potential health risk for infants in neonatal intensive care units (NICUs). This particulate consists of metals, drug crystals, glass fragments or cotton fibers and can be generated by drug packaging, incomplete reconstitution and chemical incompatibilities. In line-filters have been shown to remove micro-organisms, endotoxin, air and particles in critically ill adults and older infants, but its benefits in newborn remain to be demonstrated. Moreover, 50% of inflammatory episodes in the setting of NICUs are blood culture-negative. These episodes could be partly related to the presence of particles in the infusion lines. Methods: A multicenter randomized single-blind controlled trial was designed. All infants admitted to NICUs for which prolonged infusion therapy is expected will be enrolled in the study and randomized to the Filter or Control arm. All patients will be monitored until discharge, and data will be analyzed according to a “full analysis set”. The primary outcome is the frequency of patients with at least one sepsis-like event, defined by any association of suspected sepsis symptoms with a level of c-reactive protein (CRP) > 5mg/L in a negative-culture contest. The frequency of sepsis, phlebitis, luminal obstruction, and the duration of mechanical ventilation and of catheter days will be evaluated as secondary outcomes. The sample size was calculated at 368 patients per arm. Discussion: This is the first multicenter randomized control trial that compares in-line filtration of parenteral nutrition and other intravenous drugs to infusion without filters. Sepsis-like events are commonly diagnosed in clinical practice and are more frequent than sepsis in a positive culture contest. The risk of these episodes in the target population is estimated at 30-35%, but this data is not confirmed in the literature. If the use of in-line filters results in a significant decrease in sepsis-like events and/or in any other complications, the use of in-line filters in all intravenous administration systems may be recommended in NICUs. Trial registration: ClinicalTrials.gov, NCT05537389. Registered on 12 September 2022.

Publisher

Research Square Platform LLC

Reference21 articles.

1. Update on the Use of Filters for Parenteral Nutrition: An ASPEN Position Paper;Worthington P;Nutr Clin Pract Off Publ Am Soc Parenter Enter Nutr,2021

2. Quality-Control Analytical Methods: Particulate Matter In Injections: What is It and What are the Concerns?;Tran T;Int J Pharm Compd,2006

3. Particulate matter in injectable drug products;Langille SE;PDA J Pharm Sci Technol,2013

4. Intravenous in-line filters: filtering the evidence;Ball PA;Curr Opin Clin Nutr Metab Care,2003

5. In-line filtration reduces severe complications and length of stay on pediatric intensive care unit: a prospective, randomized, controlled trial;Jack T;Intensive Care Med,2012

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3